about
Divergence in the plasminogen-binding group a streptococcal M protein family: functional conservation of binding site and potential role for immune selection of variantsHER2 and uPAR cooperativity contribute to metastatic phenotype of HER2-positive breast cancerDependence on endocytic receptor binding via a minimal binding motif underlies the differential prognostic profiles of SerpinE1 and SerpinB2 in cancer.Effects on human plasminogen conformation and activation rate caused by interaction with VEK-30, a peptide derived from the group A streptococcal M-like protein (PAM).Anti-tumour/metastasis effects of the potassium-sparing diuretic amiloride: an orally active anti-cancer drug waiting for its call-of-duty?Plasminogen binding and cancer: promises and pitfalls.A key role for the urokinase plasminogen activator (uPA) in invasive Group A streptococcal infection.The plasminogen-binding group A streptococcal M protein-related protein Prp binds plasminogen via arginine and histidine residues.SerpinB2 (PAI-2) Modulates Proteostasis via Binding Misfolded Proteins and Promotion of Cytoprotective Inclusion Formation.Plasminogen binding and activation at the breast cancer cell surface: the integral role of urokinase activity.Gastric cancer stem cells: evidence, potential markers, and clinical implications.Synthesis and preliminary evaluation of 5,7-dimethyl-2-aryl-3H-pyrrolizin-3-ones as angiogenesis inhibitors.Is plasminogen deployed as a Streptococcus pyogenes virulence factor?Plasminogen binding by group A streptococcal isolates from a region of hyperendemicity for streptococcal skin infection and a high incidence of invasive infection.The topology of plasminogen binding and activation on the surface of human breast cancer cellsN-alkylated isatins evade P-gp mediated efflux and retain potency in MDR cancer cell linesRevisiting the biological roles of PAI2 (SERPINB2) in cancer.Circulating tumour cells in regionally metastatic cutaneous squamous cell carcinoma: A pilot study.Forty years later and the role of plasminogen activator inhibitor type 2/SERPINB2 is still an enigma.Bacterial plasminogen receptors: mediators of a multifaceted relationship.PD-L1 expression predicts longer disease free survival in high risk head and neck cutaneous squamous cell carcinoma.Improved pharmacokinetic and biodistribution properties of the selective urokinase inhibitor PAI-2 (SerpinB2) by site-specific PEGylation: implications for drug delivery.p16 expression in cutaneous squamous cell carcinoma of the head and neck is not associated with integration of high risk HPV DNA or prognosis.Targeting urokinase and the transferrin receptor with novel, anti-mitotic N-alkylisatin cytotoxin conjugates causes selective cancer cell death and reduces tumor growth.Small molecule antagonists of the urokinase (uPA): urokinase receptor (uPAR) interaction with high reported potencies show only weak effects in cell-based competition assays employing the native uPAR ligand.Molecular competition between plasminogen activator inhibitors type -1 and -2 for urokinase: Implications for cellular proteolysis and adhesion in cancer.Synthesis and hydrolytic evaluation of acid-labile imine-linked cytotoxic isatin model systems.Selective targeting of 2'-deoxy-5-fluorouridine to urokinase positive malignant cells in vitro.Cell surface antigens of Mycoplasma species bovine group 7 bind to and activate plasminogen.N-phenethyl and N-naphthylmethyl isatins and analogues as in vitro cytotoxic agents.In vitro cytotoxicity evaluation of some substituted isatin derivatives.Kinetic analysis of plasminogen activator inhibitor type-2: urokinase complex formation and subsequent internalisation by carcinoma cell lines.A structural basis for differential cell signalling by PAI-1 and PAI-2 in breast cancer cells.P2X7 receptor activation induces cell death and CD23 shedding in human RPMI 8226 multiple myeloma cells.Extracellular matrix modulates the function of human melanocytes but not melanoma cells.Interaction between the P14 residue and strand 2 of beta-sheet B is critical for reactive center loop insertion in plasminogen activator inhibitor-2.In vitro cytotoxicity of bismuth-213 (213Bi)-labeled-plasminogen activator inhibitor type 2 (alpha-PAI-2) on human breast cancer cells.Plasmin(ogen) acquisition by group A Streptococcus protects against C3b-mediated neutrophil killing.PZP and PAI-2: Structurally-diverse, functionally similar pregnancy proteins?An investigation into the cytotoxicity and mode of action of some novel N-alkyl-substituted isatins.
P50
Q24297494-FD5E8449-CA13-47FE-B63F-C380E62DA992Q28085413-E073B62D-0F97-4322-BF31-D9733CF871A5Q30502082-62DD8D6D-8542-4F2C-ACED-2AD6FFCD288FQ33759211-AA04DFA7-CE6B-4E34-BF2C-C983E869DA74Q34182861-12524B50-9AA9-4438-B50E-670F1AE37103Q34191118-4C76A2CC-1688-41A9-8D69-9BBCB171CAE1Q34819613-0CED2AA4-30A6-4B7D-B8A6-979687C35A2AQ35634718-BFD0BD31-D462-4681-841F-ED13014B9DC5Q35666031-826FFEB6-8621-420E-B36B-F603BE308335Q35749341-05ABC3E5-88A0-462D-A068-7D907B9C3E54Q35795934-0516EE2C-CAFE-418E-845D-5E354DD30861Q35934934-16DABFEA-9D38-45C7-BB40-43A507C02511Q36151856-786CCB29-FEED-4594-BFC7-EB044A7382F4Q36227332-A3042F6E-8168-48EC-B517-F534BB43513EQ36643348-DAE07179-B2EA-4175-A324-9ACA13B8B028Q37096409-F37A4967-DBF2-4CD9-9C07-6080045B576EQ37189305-6CAC1446-FC7C-4DE6-B2EE-7551DE0160A8Q37565057-F11B92D4-24D2-4D22-B69A-39CC45CA268DQ37909231-E03A3E79-C69F-4B2E-964B-952E214DE4A9Q38057217-E70FEF6F-1A3C-40F1-AAD2-2CB3BAB14149Q38699598-16D3F21C-AA48-45E1-BFC7-FF16F1F3F089Q38955588-5BA48BBA-45AB-4DE6-906E-308BA925A9B0Q39405599-C4154ECA-27BE-427A-9528-0245A3016958Q39438198-4C43A88C-E110-4F26-BA6C-B7542CE3D9DEQ39567545-0F8611A1-B914-41EB-B067-A1251A6A0CC1Q39593251-8BB3F282-F582-4612-8ED6-9BA668563D28Q39595324-A9F8F140-6CB4-4FC1-B2B4-94FFCE2B63AAQ39719330-E511FB81-66AD-4919-A571-B8101EC95D48Q39792392-E96E98EA-12BF-4A7C-A737-834D83B5511BQ40027268-7304B3BF-C072-4AB1-B40D-9DD97D0FB72BQ40211510-51192B28-B7B6-455D-AB6B-DA2E026C02EAQ40546156-B4D3FC65-999E-4E88-A6C3-50CF359EC8AAQ41823150-0BDA5DC2-5E48-4942-9E01-EBE2BB12BF85Q42963837-A57B5B52-B4F9-409A-9238-722AA05DA088Q43464239-ADABF0B9-7BDB-4010-A8A2-45771EC7EDC6Q43736465-373AAD94-A026-4396-8D75-605EC15F6FD0Q43907665-8BBCFE5D-818C-4EF0-B583-CC1F396C0335Q46181019-641C92DD-CEF5-4829-BB53-0F161F5463C5Q46307377-96EBDE8E-3968-4431-B401-9DA57332B2E2Q46988028-34ECBCE1-61AE-42D3-941C-F788BD9A356F
P50
description
hulumtuese
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Marie Ranson
@ast
Marie Ranson
@en
Marie Ranson
@es
Marie Ranson
@fr
Marie Ranson
@nl
Marie Ranson
@sl
type
label
Marie Ranson
@ast
Marie Ranson
@en
Marie Ranson
@es
Marie Ranson
@fr
Marie Ranson
@nl
Marie Ranson
@sl
prefLabel
Marie Ranson
@ast
Marie Ranson
@en
Marie Ranson
@es
Marie Ranson
@fr
Marie Ranson
@nl
Marie Ranson
@sl
P1053
A-6324-2008
P106
P1153
7005465112
P21
P31
P3829
P496
0000-0002-5570-9645